Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. J Clin Invest. 2023 08 15; 133(16).
View in:
PubMed
Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. Cancer Res. 2023 Jul 14.
View in:
PubMed
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat Cancer. 2023 07; 4(7):1016-1035.
View in:
PubMed
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol. 2023 Jul; 34(7):589-604.
View in:
PubMed
Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors. Nat Commun. 2023 04 14; 14(1):2122.
View in:
PubMed
The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells. Commun Biol. 2023 01 18; 6(1):65.
View in:
PubMed
Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023 03; 615(7950):158-167.
View in:
PubMed
New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay. Adv Healthc Mater. 2023 06; 12(14):e2201784.
View in:
PubMed
Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. Cells. 2022 Nov 08; 11(22).
View in:
PubMed
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer. Cancer Res. 2022 11 02; 82(21):4079-4092.
View in:
PubMed
Preclinical models for development of immune-oncology therapies. Immuno-oncol Insights. 2022; 3(8):379-398.
View in:
PubMed
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer. 2022 10; 3(10):1228-1246.
View in:
PubMed
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. Cancer Cell. 2022 10 10; 40(10):1128-1144.e8.
View in:
PubMed
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1. Nat Commun. 2022 08 25; 13(1):4998.
View in:
PubMed
Activation of Tumor-Cell STING Primes NK-Cell Therapy. Cancer Immunol Res. 2022 08 03; 10(8):947-961.
View in:
PubMed
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040.
View in:
PubMed
Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies. Cancers (Basel). 2022 Jul 22; 14(15).
View in:
PubMed
STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proc Natl Acad Sci U S A. 2022 07 12; 119(28):e2111003119.
View in:
PubMed
A Robust Method for Perfusable Microvascular Network Formation In Vitro. Small Methods. 2022 06; 6(6):e2200143.
View in:
PubMed
Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. Cancer Res. 2022 01 15; 82(2):248-263.
View in:
PubMed
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022 03; 17(3):399-410.
View in:
PubMed
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 Sep; 13(609):eabb3738.
View in:
PubMed
A robust vasculogenic microfluidic model using human immortalized endothelial cells and Thy1 positive fibroblasts. Biomaterials. 2021 09; 276:121032.
View in:
PubMed
Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nat Genet. 2021 06; 53(6):881-894.
View in:
PubMed
KRAS G12C inhibition and innate immune targeting. Expert Opin Ther Targets. 2021 03; 25(3):167-174.
View in:
PubMed
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 04; 2(4):444-456.
View in:
PubMed
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 08; 11(8):1952-1969.
View in:
PubMed
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest. 2021 01 19; 131(2).
View in:
PubMed
Targeting the mutant p53 secretome. J Clin Invest. 2021 01 04; 131(1).
View in:
PubMed
Engineering approaches for studying immune-tumor cell interactions and immunotherapy. iScience. 2021 Jan 22; 24(1):101985.
View in:
PubMed
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. JCO Precis Oncol. 2020; 4.
View in:
PubMed
Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. Genet Epidemiol. 2021 02; 45(1):99-114.
View in:
PubMed
Tumor-Derived cGAMP Regulates Activation of the Vasculature. Front Immunol. 2020; 11:2090.
View in:
PubMed
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311.
View in:
PubMed
EGFR blockade activates interferon. Nat Cancer. 2020 04; 1(4):376-378.
View in:
PubMed
TBK1 Activation by VHL Loss in Renal Cell Carcinoma: A Novel HIF-Independent Vulnerability. Cancer Discov. 2020 03; 10(3):348-350.
View in:
PubMed
Use of ExVivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 05 15; 26(10):2393-2403.
View in:
PubMed
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 01 13; 37(1):104-122.e12.
View in:
PubMed
Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nat Struct Mol Biol. 2020 01; 27(1):92-104.
View in:
PubMed
Clonal Selection Drives NF-?B Activation in Recurrent Nasopharyngeal Carcinoma. Cancer Res. 2019 12 01; 79(23):5915-5916.
View in:
PubMed
Phosphorylation of RAB7 by TBK1/IKKe Regulates Innate Immune Signaling in Triple-Negative Breast Cancer. Cancer Res. 2020 01 01; 80(1):44-56.
View in:
PubMed
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019 10; 9(10):1372-1387.
View in:
PubMed
Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion. Cancer Res. 2019 08 01; 79(15):3903-3915.
View in:
PubMed
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019 Jan 10; 176(1-2):404.
View in:
PubMed
The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv. 2018 12 11; 2(23):3428-3442.
View in:
PubMed
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
View in:
PubMed
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 11 01; 175(4):998-1013.e20.
View in:
PubMed
Tumor cGAMP Awakens the Natural Killers. Immunity. 2018 10 16; 49(4):585-587.
View in:
PubMed
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip. 2018 10 09; 18(20):3129-3143.
View in:
PubMed
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov. 2019 01; 9(1):34-45.
View in:
PubMed
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunol Res. 2018 12; 6(12):1511-1523.
View in:
PubMed
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. Cancer Cell. 2018 09 10; 34(3):439-452.e6.
View in:
PubMed
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
View in:
PubMed
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. Clin Lung Cancer. 2018 11; 19(6):e853-e859.
View in:
PubMed
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019 02; 37(1):159-165.
View in:
PubMed
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018 08; 24(8):1143-1150.
View in:
PubMed
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clin Cancer Res. 2018 10 01; 24(19):4854-4864.
View in:
PubMed
Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol. 2018 04 25; 9(4):145.
View in:
PubMed
RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic? Clin Cancer Res. 2018 03 15; 24(6):1243-1245.
View in:
PubMed
Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018 01; 118(1):9-16.
View in:
PubMed
ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018 02 15; 78(4):1044-1057.
View in:
PubMed
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
View in:
PubMed
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233.
View in:
PubMed
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. Annu Rev Med. 2018 01 29; 69:333-347.
View in:
PubMed
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Syst. 2017 08 23; 5(2):105-118.e9.
View in:
PubMed
Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma. Cancer Discov. 2017 08; 7(8):799-801.
View in:
PubMed
The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. Oncogene. 2017 09 07; 36(36):5145-5157.
View in:
PubMed
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov. 2017 08; 7(8):852-867.
View in:
PubMed
MicroRNA-140 mediates RB tumor suppressor function to control stem cell-like activity through interleukin-6. Oncotarget. 2017 Feb 21; 8(8):13872-13885.
View in:
PubMed
Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. Oncoimmunology. 2017; 6(3):e1284720.
View in:
PubMed
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunol Res. 2016 12; 4(12):1038-1048.
View in:
PubMed
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. Sci Rep. 2016 08 19; 6:31745.
View in:
PubMed
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. Semin Cell Dev Biol. 2016 10; 58:127-35.
View in:
PubMed
Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol. 2016 05; 34(5):539-46.
View in:
PubMed
Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. Cancer Immunol Res. 2016 06; 4(6):520-30.
View in:
PubMed
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 Mar 01; 76(5):999-1008.
View in:
PubMed
Doxycycline: new tricks for an old drug. Oncotarget. 2015 Aug 14; 6(23):19336-7.
View in:
PubMed
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell. 2015 Aug 06; 59(3):345-358.
View in:
PubMed
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015 Aug; 3(8):855-63.
View in:
PubMed
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. Clin Lung Cancer. 2015 Sep; 16(5):e101-4.
View in:
PubMed
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014 Dec 08; 26(6):909-922.
View in:
PubMed
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014 Dec; 124(12):5411-23.
View in:
PubMed
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A. 2014 Nov 11; 111(45):E4869-77.
View in:
PubMed
Targeting pathways downstream of KRAS in lung adenocarcinoma. Pharmacogenomics. 2014 Aug; 15(11):1507-18.
View in:
PubMed
Targeting cytokine networks in KRAS-driven tumorigenesis. Expert Rev Anticancer Ther. 2014 Aug; 14(8):869-71.
View in:
PubMed
Interactive Medical case. Off balance. N Engl J Med. 2014 Jun 12; 370(24):e37.
View in:
PubMed
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8.
View in:
PubMed
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 03; 124(1):13-23.
View in:
PubMed
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014 Apr; 4(4):452-65.
View in:
PubMed
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013 Sep; 3(9):1044-57.
View in:
PubMed
Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep. 2013 Mar 28; 3(3):747-58.
View in:
PubMed
Functional genomics and cancer drug target discovery. Curr Opin Mol Ther. 2010 Jun; 12(3):284-93.
View in:
PubMed
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 05; 462(7269):108-12.
View in:
PubMed
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32.
View in:
PubMed
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009 May 29; 137(5):821-34.
View in:
PubMed
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
View in:
PubMed
Destablization of the Cancer Genome. DeVita, Hellman & Rosenberg's Cancer: Principle and Practice of Oncology. 2008; 35-51.
Destablization of the Cancer Genome. DeVita, Hellman & Rosenberg's Cancer: Principle and Practice of Oncology. 2008; 35-51.
Pharmacology of Cancer: Genome Synthesis, Stability, and Maintenance. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 2008; 675-699.
Pharmacology of Cancer: Signal Transduction. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 2008; 701-717.
Hematology-Oncology. Pocket Medicine. 2008; 5.1-5.36.
Pharmacology of Cancer: Genome Synthesis, Stability, and Maintenance. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 2008; 675-699.
Pharmacology of Cancer: Signal Transduction. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 2008; 701-717.
Hematology-Oncology. Pocket Medicine. 2008; 5.1-5.36.
Systemic mastocytosis: current classification and novel therapeutic options. Clin Adv Hematol Oncol. 2006 Oct; 4(10):768-75.
View in:
PubMed
Nuclear tumor suppressors in space and time. Trends Cell Biol. 2005 Jul; 15(7):378-85.
View in:
PubMed
Eosinophilic gastroenteritis associated with systemic lupus erythematosus. J Clin Gastroenterol. 2004 Nov-Dec; 38(10):883-6.
View in:
PubMed
A-type lamins regulate retinoblastoma protein function by promoting subnuclear localization and preventing proteasomal degradation. Proc Natl Acad Sci U S A. 2004 Jun 29; 101(26):9677-82.
View in:
PubMed
Nuclear reorganization of mammalian DNA synthesis prior to cell cycle exit. Mol Cell Biol. 2004 Jan; 24(2):595-607.
View in:
PubMed
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A. 2003 Dec 23; 100(26):15601-6.
View in:
PubMed
Nuclear Organization of Mammalian DNA Replication. 2002.
RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest. Mol Cell Biol. 2001 Apr; 21(8):2918-32.
View in:
PubMed
Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem. 2000 Nov 24; 275(47):37101-9.
View in:
PubMed
Nuclear organization of DNA replication in primary mammalian cells. Genes Dev. 2000 Nov 15; 14(22):2855-68.
View in:
PubMed
NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev. 2000 Sep 15; 14(18):2283-97.
View in:
PubMed
Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol. 1996 Sep; 16(9):5210-8.
View in:
PubMed